Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 5/20 | 0.35 |
| ▸ | ANPEP | P15144 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824305 | 1.00 | IDO1 (0.40) | IDO1PLAUPARP1HTR2AKDM1A | |
| SCHEMBL11552076 | 0.81 | PLAU (0.45) | IDO1PLAUPARP1HTR2AKDM1A | |
| Hydrochloric Acid SCHEMBL11558401 | 0.79 | PLAU (0.44) | IDO1PLAUPARP1KDM1AANPEP | |
| SCHEMBL6143052 | 0.77 | IDO1 (0.43) | IDO1PLAUHTR2AKDM1AANPEP | |
| SCHEMBL3363708 | 0.75 | IDO1 (0.38) | IDO1PARP1 | |
| SCHEMBL2524855 | 0.74 | PARP1 (0.36) | IDO1PARP1ANPEPCA1CA2 | |
| SCHEMBL8161816 | 0.74 | CYP19A1 (0.37) | IDO1PLAUPARP1 | |
| SCHEMBL15233622 | 0.74 | PARP1 (0.36) | IDO1PARP1HTR2AANPEPCA1 | |
| SCHEMBL225642 | 0.74 | PARP1 (0.36) | IDO1PARP1CA1CA2 | |
| SCHEMBL18026599 | 0.74 | PARP1 (0.36) | IDO1PARP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117255689-A | NMN and derivatives for the treatment of depression and/or anxiety in patients suffering from one form of Parkinson's disease | 努瓦米德公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |